Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Additional Information (Detail)

Commitments and Contingencies - Additional Information (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014 Milestone	Dec. 31, 2012
UFRF License Agreements [Member]
Commitment And Contingencies [Line Items]
Company's obligation to pay from percentage of selling price of product	5.00%
Company's obligation to pay from all revenue received from sublicenses	22.00%
One-time commercialization fee that would due on the first anniversary of first commercial sale	$ 5,000
Post-commercialization minimum royalty payments	50,000
Minimum total cumulative royalties required to be paid for One-time additional royalty payment	2,000,000
One-time additional payment to UFRF as a percentage of total royalties due to UFRF	10.00%
Commercial sales	0
Commercialization fees	0
Minimum annual maintenance payment per license agreement	10,000
Aggregate minimum annual maintenance payment	20,000
Quarterly maintenance payment to UFRF under installment plan	5,000
Termination notice period	90 days
Texas A and M University License [Member]
Commitment And Contingencies [Line Items]
Company's obligation to pay from percentage of selling price of product	5.00%
Initial payment to Texas A&M	5,000
Minimum consideration for the continuation of the license agreement	15,000
Minimum annual amount to Texas A&M	100,000
Annual maintenance payment under licensing agreement with Texas A&M	100,000
Date of milestone achievement under licensing agreement with Texas A&M	Jun. 01, 2025
Maintenance payment under licensing agreement with Texas A&M	400,000
Maximum period to cure the breach	60 days
Termination notice period	90 days
Texas A and M University License [Member] \| Phase I Clinical Trial [Member]
Commitment And Contingencies [Line Items]
Date of milestone achievement under licensing agreement with Texas A&M	Jun. 01, 2015
Maintenance payment under licensing agreement with Texas A&M	50,000
Texas A and M University License [Member] \| Phase II Clinical Trial [Member]
Commitment And Contingencies [Line Items]
Date of milestone achievement under licensing agreement with Texas A&M	Jun. 01, 2019
Maintenance payment under licensing agreement with Texas A&M	100,000
Texas A and M University License [Member] \| Phase III Clinical Trial [Member]
Commitment And Contingencies [Line Items]
Date of milestone achievement under licensing agreement with Texas A&M	Jun. 01, 2022
Maintenance payment under licensing agreement with Texas A&M	150,000
Texas A and M University License [Member] \| Minimum [Member]
Commitment And Contingencies [Line Items]
Company's obligation to pay from percentage of selling price of product	2.00%
Probiotics ECC [Member]
Commitment And Contingencies [Line Items]
Company's obligation to pay from percentage of selling price of product	10.00%
Maximum period to cure the breach	60 days
Termination notice period	90 days
Milestone amount payable one	2,000,000
Milestone measurement period	30 days
Milestone amount payable two	5,000,000
Milestone amount payable three	$ 10,000,000
Lantibiotic Exclusive Channel Collaboration (ECC) [Member]
Commitment And Contingencies [Line Items]
Company's obligation to pay from percentage of selling price of product	25.00%
Company's obligation to make payment from all revenue received from sublicensing	50.00%
Number of shares issued		4,392,425
Maximum percentage of primary investment securities to investment of shares issued	10.00%
Number of milestones achieved	0
Termination notice period	90 days
Lantibiotic Exclusive Channel Collaboration (ECC) [Member] \| Investigational New Drug Application [Member]
Commitment And Contingencies [Line Items]
Percentage of number of shares of common stock equal to Base Shares	1.00%
Lantibiotic Exclusive Channel Collaboration (ECC) [Member] \| Clinical Study Phase 2 [Member]
Commitment And Contingencies [Line Items]
Percentage of number of shares of common stock equal to Base Shares	1.50%
Lantibiotic Exclusive Channel Collaboration (ECC) [Member] \| Clinical Study Phase 3 [Member]
Commitment And Contingencies [Line Items]
Percentage of number of shares of common stock equal to Base Shares	2.00%
Lantibiotic Exclusive Channel Collaboration (ECC) [Member] \| Filing of First Investigational New Drug Application [Member]
Commitment And Contingencies [Line Items]
Percentage of number of shares of common stock equal to Base Shares	2.50%
Lantibiotic Exclusive Channel Collaboration (ECC) [Member] \| First Regulatory Approval of Oragenics Product [Member]
Commitment And Contingencies [Line Items]
Percentage of number of shares of common stock equal to Base Shares	3.00%